AC
TXMD icon

Ascend Capital’s TherapeuticsMD TXMD Stock Holding History

Ascend Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2.31M Buy
+7,028
New +$2.15M 0.12% 130

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Ascend Capital's TXMD Position: Q3 2018 in Review

Ascend Capital opened a new position in TherapeuticsMD (TXMD) in Q3 2018: 7,028 shares worth $2.31M. The stake represents 0.12% of the portfolio and ranks #130 among its holdings.

155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

  • Ascend Capital held 7,028 shares of TherapeuticsMD worth $2.31M as of Q3 2018.
  • TherapeuticsMD was a new Ascend Capital position in Q3 2018.
  • TherapeuticsMD made up 0.12% of Ascend Capital's portfolio in Q3 2018, its #130 holding.
  • 155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.